This site is intended for health professionals only

Clinical trials firm set for US expansion

teaser

UK-based specialist clinical trials firm Phlexglobal is expanding into the USA with a planned new facility in Philadelphia or Boston.

CEO Nigel Murgatroyd said the move followed a sustained period of growth in the UK and increasing interest from current and potential client companies.

He said the company, based in Amersham, UK, had successfully presented on electronic trial master files (TMFs) at the recent DIA Conference for Electronic Document Management in Philadelphia.

“The trial master file has global reach and, as this is one of our core business services, having an operation in the States is essential,” said Mr Murgatroyd.

“After a successful visit to Philadelphia for the DIA event we are now looking there, and in Boston, for a suitable new facility which we hope will be open in the summer.”

He said Phlexglobal specialised in document management, resourcing, training, archiving and general study support services.

It counted 15 of the world’s top 20 pharmaceutical companies as its clients.

He said last year the firm launched its PhlexEview service, an end-to-end TMF solution aimed at allowing secure logical electronic searching and viewing of centralised TMF documentation from sponsors, subsidiaries, clinical research organisations and field-based personnel from anywhere in the world at any time.

He added: “We are initially looking to take our PhlexEviewTM and TMF solutions, and associated services such as Task Force and Training, to America as that is where the current demand lies.

“There is a concern from American companies about sending documentation internationally and so opening a US facility will reduce the transportation required and increase customer confidence.”

He said globally, Phlexglobal was also looking to expand into Europe with the additional key service of resourcing offered.

To facilitate bringing resourcing operations to Europe, a network of offices was planned over the next three years.

Phlexglobal






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x